Results 31 to 40 of about 34,440,044 (184)

The glucagon-like Peptide-2 [PDF]

, 2011
Multiple peptide hormones produced within the gastrointestinal system act also in the central nervous system and aid in the regulation of energy homeostasis and metabolism. The list of these peptides is progressively increasing and includes glucagon-like
Mule, Flava, MULE', Flavia
core  

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia

Clinical Medicine Insights: Endocrinology and Diabetes, 2021
A relatively recent addition to the arsenal of antidiabetic drugs used for the treatment of type 2 diabetes mellitus (T2DM) has been the “incretin mimetics,” a group of drugs that work on the glucagon-like peptide-1 (GLP-1) receptor and enhance insulin ...
Daria Ja’arah, Mazhar Salim Al Zoubi, Gamal Abdelhady, Firas Rabi, Murtaza M Tambuwala   +4 more
doaj   +1 more source

Clinical pharmacology of glucagon-like peptide-1 receptor agonists

Hormones, 2018
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an important asset in the armamentarium for the treatment of type 2 diabetes mellitus (type 2 DM). Incretin failure is a critical etiopathogenetic feature of type 2 DM, which, if reversed, results in improved glycaemic control.
Sfairopoulos, D., Liatis, S., Tigas, S., Liberopoulos, E.   +3 more
openaire   +3 more sources

A real-world propensity analysis of the impact of GLP-1 receptor agonists on cancer therapy-related cardiac dysfunction

Communications Medicine
Background Heart damage caused by cancer treatment can lead to heart failure, hospital admission, and death. Medications known as glucagon-like peptide-1 receptor agonists are widely used to treat type 2 diabetes with cardioprotective potentials. Whether
Jheng-Yan Wu, Yu-Min Lin, Mei-Chuan Lee, Chung-Han Ho, Pei Yu Jhou, Wei-Ting Chang   +5 more
doaj   +1 more source

Comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? [PDF]

, 2014
Adam M.
Deane, A., Horowitz, M.
core   +1 more source

Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1

International Journal of Endocrinology, 2015
The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels.
XingChun Wang, Huan Liu, Jiaqi Chen, Yan Li, Shen Qu   +4 more
doaj   +1 more source

Systematic Review of Glucagon-Like Peptide-1 Agonists to Manage Weight Gain in Patients Taking Antipsychotics [paper] [PDF]

School of Nursing CapstonesPatients struggling with schizophrenia have significant weight gain and lower life expectancy than the general population. These differences may be the result of commonly prescribed antipsychotic medications.
Nash, Samuel
core   +1 more source

Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology

Journal of Diabetology
A novel therapeutic target for diabetes mellitus is incretin-based therapies, glucagon-like peptide-1, and glucose-dependent insulinotropic polypeptides are released from the gastrointestinal (GI) tract and act on beta cells of pancreatic islets by ...
Bhaskar Pal, Moitreyee Chattopadhyay
doaj   +1 more source

Glucagon Receptor Signaling and Lipid Metabolism

Frontiers in Physiology, 2019
Glucagon is secreted from the pancreatic alpha cells upon hypoglycemia and stimulates hepatic glucose production. Type 2 diabetes is associated with dysregulated glucagon secretion, and increased glucagon concentrations contribute to the diabetic ...
Katrine D. Galsgaard, Katrine D. Galsgaard, Jens Pedersen, Jens Pedersen, Filip K. Knop, Filip K. Knop, Filip K. Knop, Jens J. Holst, Jens J. Holst, Nicolai J. Wewer Albrechtsen, Nicolai J. Wewer Albrechtsen, Nicolai J. Wewer Albrechtsen   +11 more
doaj   +1 more source

Diffuse Podocytopathy Associated With Semaglutide

Annals of Internal Medicine: Clinical Cases
We present 3 cases of biopsy-proven minimal change disease occurring in close temporal association with semaglutide (glucagon-like peptide 1 receptor agonists) exposure.
Rose Mary Attieh, Grant Kirby, Yang Yihe, Serena Bagnasco, Andrew A. Moses, Mahmoud Abdelaziz, Rimda Wanchoo, Samir Gautam, Astrid Weins, Kenar D. Jhaveri   +9 more
doaj   +1 more source